ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION On January 7, 2021, Revance Therapeutics, Inc. (the "Company") issued a press release, which provided a corporate and product pipeline update and anticipated milestones for 2021. The Company also reported on a preliminary and unaudited basis the expected range of revenue from sales of the RHA® Collection for the three months and year ended December 31, 2020. These are preliminary estimates based on currently available information and do not present all necessary information for a complete understanding of the Company's financial condition as of December 31, 2020, or the Company's results of operations for the year ended December 31, 2020. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in Item 2.02 of this Current Report on From 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing, regardless of any general incorporation language in such filing.

ITEM 8.01 OTHER EVENTS

On January 7, 2021, the Company issued a press release titled "Revance Provides Corporate Update and Anticipated Milestones for 2021." A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.




ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
Number         Description
  99.1           Press Release dated January 7, 2021
104            Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses